Navigation Links
Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:5/17/2011

WAYNE, N.J., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL.  

"Bayer has built a pipeline of oncology compounds, including several in late-stage development, and our researchers are working tirelessly to advance their development," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.  "At ASCO, we are presenting data from studies evaluating these compounds."  

Bayer-sponsored Phase II and III studies evaluating the investigational compounds in Bayer's pipeline being presented at ASCO include:

Radium-223 Chloride

  • Alkaline Phosphatase (ALP) Normalization and Overall Survival in Patients With Bone Metastases From Castration-Resistant Prostate Cancer (CRPC) Treated with Radium-223
    • Abstract #4620, Genitourinary Cancer Poster Session
    • Sunday, June 5, 8:00 am - 12:00 pm, Hall A, Poster Board 7D

Radium-223 chloride is an investigational agent and is not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) or other Health Authorities.

About Oncology at Bayer

Bayer is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer.  With several compounds in clinical development, Bayer's oncology portfolio demonstrates the Company's commitment to developing innovative cancer therapies.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

BAYER® and the Bayer Cross® are trademarks of Bayer.

Contact:
David Freundel, 973-305-5310
E-Mail: david.freundel@bayer.com

Forward-Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 ... 2017 to stockholders of record as of the close of ... subject to approval of the Board of Directors and may ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital ... environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new ... robot that uses UVC light energy to kill deadly pathogens such as C. diff ... Tru-D SmartUVC ... Tru-D in action in a ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple Rehab Watch Hill , ... received training and certification in Closed Pulse Irrigation™ (CPI) for wound care. ... from the Centers for Medicare and Medicaid Services, to have a CPI machine that ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s Beauty and Pleasures ... the struggles faced while hoping for a better life. “Without Love’s Beauty and ... Bernewitz, who spent 13 years working with deprived/neglected adolescents and almost 20 years ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/22/2017)... Overland Park, KS (PRWEB) , ... August 22, 2017 , ... ... sellers of products to fight Fatigue . , As the stress of modern ... to keep up the pace. Constant use of artificial stimulants can trap people in ...
Breaking Medicine News(10 mins):